GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » ROE % Adjusted to Book Value

Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) ROE % Adjusted to Book Value : 6.62% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co ROE % Adjusted to Book Value?

Biocytogen Pharmaceuticals (Beijing) Co's ROE % for the quarter that ended in Dec. 2024 was 21.65%. Biocytogen Pharmaceuticals (Beijing) Co's PB Ratio for the quarter that ended in Dec. 2024 was 3.27. Biocytogen Pharmaceuticals (Beijing) Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 6.62%.

Biocytogen Pharmaceuticals (Beijing) Co ROE % Adjusted to Book Value Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co ROE % Adjusted to Book Value Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
- - -6.52 -5.65 1.28

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only -7.94 -4.53 -6.49 -3.97 6.62

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's ROE % Adjusted to Book Value falls into.


;
;

Biocytogen Pharmaceuticals (Beijing) Co ROE % Adjusted to Book Value Calculation

Biocytogen Pharmaceuticals (Beijing) Co's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=4.18% / 3.27
=1.28%

Biocytogen Pharmaceuticals (Beijing) Co's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=21.65% / 3.27
=6.62%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biocytogen Pharmaceuticals (Beijing) Co ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » ROE % Adjusted to Book Value
Comparable Companies
HKSE:02105 HKSE:02142 HKSE:02256 HKSE:00775 HKSE:06660 HKSE:02480 HKSE:02157 HKSE:06955 HKSE:01672 HKSE:02616 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
02315:Hong Kong
Address
12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN
Website
https://www.biocytogen.com.cn
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines